Reports Q3 revenue $75.182M, consensus $75.73M. “During our fiscal third quarter, we took another significant step in our transformation with the divestiture of our PICC and Midline product portfolios, further strengthening our balance sheet and providing us with an opportunity to enhance our focus on the growth of our Med Tech portfolio,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “We saw a strong pick up in growth from both our Med Tech and Med Device portfolios during the quarter and continue to drive toward meaningful margin expansion and profitability.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- Options Volatility and Implied Earnings Moves Today, April 04, 2024
- ANGO Earnings this Week: How Will it Perform?
- AngioDynamics settles litigation with Becton Dickinson
- Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024
- AngioDynamics price target raised to $18 from $17 at Canaccord